Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 5.72%
H: 3.18%
C: -3.82%
first disease biopharma for
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.17%
H: 0.08%
C: -1.9%
disease kidney treatment pharmaceuticals for study
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: 4.42%
H: 3.11%
C: -9.89%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FRLN | $6.48 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
disease cell meeting parkinson’s therapy
Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight
Published: 2024-04-24 (Crawled : 22:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
OTLK | News P | $8.2 0.0% 240K
|
Health Technology
| Email alert
Add to watchlist
KOD | News | $3.37 1.2% 1.19% 340K
|
Health Technology
| Email alert
Add to watchlist
OPT | News | $3.46 2.98% 2.89% 8.2K
|
Health Technology
| Email alert
Add to watchlist
disease market
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.405 -0.54% -0.55% 82K
|
Professional, Scientific, and T...
|
| O: 2.17%
H: 5.06%
C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
WGS | $11.82 -1.5% -1.52% 180K
|
Professional, Scientific, and T...
|
| O: 4.71%
H: 22.87%
C: 17.3%
partnership rare disease health
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
NRSN | News | $1.33 -2.21% -2.26% 130K
|
|
| O: -1.41%
H: 2.86%
C: -3.57%
precision disease ongoing alzheimer's collaboration trial
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: 0.33%
H: 0.0%
C: 0.0%
disease services biomarker blood risk alzheimer's diagnostics
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CGTX | News | $2.0 0.0% 110K
|
|
| O: -2.17%
H: 7.78%
C: 3.33%
disease alzheimer’s treat for therapeutics platform
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 0.02% 3.4K
|
Manufacturing
|
| O: -3.38%
H: 0.0%
C: 0.0%
ccl24 disease association publication sclerosis
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.87 -0.29% -0.29% 630K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 0.0%
H: 7.32%
C: -1.95%
disease neurology system meeting parkinson’s therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -5.0%
H: 4.19%
C: 2.86%
disease vyvgart for
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | News | $4.56 -1.72% -1.75% 560K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN 4 d | $1.73 -4.95% -5.2% 300K
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.57 -0.22% -0.22% 160K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.